May 14, 2019 / 11:42 AM / 2 months ago

Myovant Sciences' uterine fibroids combo therapy meets main goal in study

May 14 (Reuters) - Myovant Sciences Ltd on Tuesday said its combination therapy met the main goal of a late-stage study testing the treatment in women with uterine fibroids.

The company said 73.4% of women receiving the once-daily treatment showed a greater reduction in menstrual blood loss compared with 18.9% of women receiving placebo. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shailesh Kuber)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below